viking therapeutics vk2735 - Search News

News

Viking Therapeutics Stock Tanks

The Motley Fool on MSN · 2h

Is Beaten-Down Viking Therapeutics Stock a Buy on the Dip?

Viking Therapeutics (VKTX 5.71%) fell a whopping 39.2% from their previous close on Tuesday, Aug. 19. Investors were reacting to new clinical trial result

Viking Therapeutics: What's Happening With VKTX Stock?

The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli Lilly and Novo Nordisk.

Zacks.com on MSN · 19h

Viking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill Study

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral Dosing study, which evaluated the safety and efficacy of the oral formulation of its experimental obesity drug, VK2735.

20hon MSN

Here's Why Viking Therapeutics Bounced Back Today

Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

1don MSN

Viking Therapeutics Shares Nosedive Toward Worst Day Ever After Obesity Trial Data

The company is the latest facing historic losses as pharmaceutical firms compete to develop a weight-loss pill.

9h

Viking Therapeutics (VKTX) Slashes 42% on Huge Clinical Study Dropout Rate

We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...

12h

Viking Therapeutics: Panic Creates Opportunity

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results